Compare WD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WD | CGEM |
|---|---|---|
| Founded | 1937 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | 2020 |
| Metric | WD | CGEM |
|---|---|---|
| Price | $34.86 | $14.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $57.00 | $33.45 |
| AVG Volume (30 Days) | 395.8K | ★ 1.0M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,234,306,000.00 | N/A |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $12.04 | $195.22 |
| P/E Ratio | $65.67 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $36.10 | $5.68 |
| 52 Week High | $90.00 | $23.19 |
| Indicator | WD | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 27.33 | 28.33 |
| Support Level | N/A | $11.87 |
| Resistance Level | $52.37 | $16.31 |
| Average True Range (ATR) | 1.25 | 1.26 |
| MACD | -0.22 | -0.66 |
| Stochastic Oscillator | 0.00 | 12.11 |
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.